Figure 3. Construction of an immune-related prognostic signature for HNSCC. (A) Eighteen immune-related genes selected by LASSO Cox analysis. (B) A 10-fold cross-validation for the optimal penalty parameter lambda. (C, D) The risk score distribution of HNSCC patients in the training and validation sets. (E, F) Survival status and duration of patients in the training and validation sets. (G, H) Survival curves for the low and high risk groups in the training and validation sets.